Showing 601-610 of 2046 results for "".
Biosimilars: What's Coming for Labeling?
https://practicaldermatology.com/topics/practice-management/biosimilars-whats-coming-for-labeling/20934/The public comment period on draft labeling guidance will end next month.When Disruption Spells Opportunity
https://practicaldermatology.com/topics/practice-management/when-disruption-spells-opportunity/20950/Making the case for teledermatology in the new millennium.Finding and Hiring the Right Employees
https://practicaldermatology.com/topics/practice-management/finding-and-hiring-the-right-employees/20966/Are These Three Weaknesses Lurking In Your LLC Or FLP?
https://practicaldermatology.com/topics/practice-management/are-these-three-weaknesses-lurking-in-your-llc-or-flp/21075/LLCs and FLPs are only as strong or weak as their operating documents and ongoing compliance management.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21093/Achieving Operational Success
https://practicaldermatology.com/topics/practice-management/achieving-operational-success/21203/Document your practice systems to enhance the patient experience.Tips for Consultation Success
https://practicaldermatology.com/topics/practice-management/tips-for-consultation-success/21465/How to build relationships that enhance the patient experience.Re-Considering the Psychological Components of Psoriasis
https://practicaldermatology.com/topics/psoriasis/re-considering-the-psychological-components-of-psoriasis/22962/With convincing data that show that psoriasis directly inhibits patients' daily activities and quality of life, clinicians must emphasize trust and empathy.Mobile Marketing: Time to Get on Board
https://practicaldermatology.com/topics/practice-management/mobile-marketing-time-to-get-on-board/21576/First Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.